stockportfolio.pro
Stocks / ACRS vs BVS
ACRS vs BVS
Aclaris Therapeutics, Inc. and Bioventus Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Aclaris Therapeutics, Inc. (ACRS) | Bioventus Inc. (BVS) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $7.83M | $568.09M |
| Net income (latest FY) | $-64.92M | $22.73M |
| Revenue growth (5y CAGR) | 3.8% | 12.1% |
| Net margin | -829.6% | 4.0% |
| Return on equity | -63.0% | 12.3% |
| P/E ratio | — | 21.2 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 4 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ACRS — free Open BVS — freeFrequently asked questions
Which is bigger, ACRS or BVS?
Aclaris Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, ACRS or BVS?
Over the last five fiscal years, Bioventus Inc. grew revenue faster — 12.1%/yr versus 3.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.